Feature

To screen or not to screen: lung and breast cancer


 

Although the incidence of lung cancer in the United States has been falling in recent years because of a decrease in cigarette smoking, the disease is still the third most common cancer, and the leading cause of cancer death. In March 2014, the US Preventive Services Task Force (USPSTF) updated its 2004 recommendations for lung cancer screening by commissioning a systematic evidence review of low-dose computed tomography (CT) by focusing on new evidence from randomized clinical trials published since 2004. In addition, a modeling study provided information about the optimum screening age, screening interval, and the risk-benefit ratio for screening.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Cochrane review: Trastuzumab benefit outweighs harm for advanced HER2-positive breast cancer
MDedge Hematology and Oncology
ALTTO: Dual HER2 blockade offers no survival edge in adjuvant breast cancer treatment
MDedge Hematology and Oncology
Single-agent paclitaxel fails in noninferiority trial for primary breast cancer
MDedge Hematology and Oncology
ASCO endorses "no ink on tumor" guidelines for breast cancer surgery
MDedge Hematology and Oncology
Frail women less likely to initiate hormonal therapy for breast cancer
MDedge Hematology and Oncology
Phone-based intervention helped breast cancer patients lose weight, but key question remains
MDedge Hematology and Oncology
Combined imaging differentiated benign, cancerous breast tumors
MDedge Hematology and Oncology
Adding tomosynthesis improved mammography’s cancer detection
MDedge Hematology and Oncology
Targeted sessions for targeted therapies at ASCO
MDedge Hematology and Oncology
Short-term outcomes of the implementation of a computer-based breast cancer risk assessment program during screening mammography
MDedge Hematology and Oncology